Literature DB >> 35176501

Ethical and epistemic issues in the design and conduct of pragmatic stepped-wedge cluster randomized clinical trials.

Carole A Federico1, Patrick J Heagerty2, John Lantos3, Pearl O'Rourke4, Vasiliki Rahimzadeh1, Jeremy Sugarman5, Kevin Weinfurt6, David Wendler7, Benjamin S Wilfond8, David Magnus9.   

Abstract

Stepped-wedge cluster randomized trial (SW-CRT) designs are increasingly employed in pragmatic research; they differ from traditional parallel cluster randomized trials in which an intervention is delivered to a subset of clusters, but not to all. In a SW-CRT, all clusters receive the intervention under investigation by the end of the study. This approach is thought to avoid ethical concerns about the denial of a desired intervention to participants in control groups. Such concerns have been cited in the literature as a primary motivation for choosing SW-CRT design, however SW-CRTs raise additional ethical concerns related to the delayed implementation of an intervention and consent. Yet, PCT investigators may choose SW-CRT designs simply because they are concerned that other study designs are infeasible. In this paper, we examine justifications for the use of SW-CRT study design, over other designs, by drawing on the experience of the National Institutes of Health's Health Care Systems Research Collaboratory (NIH Collaboratory) with five pragmatic SW-CRTs. We found that decisions to use SW-CRT design were justified by practical and epistemic reasons rather than ethical ones. These include concerns about feasibility, the heterogeneity of cluster characteristics, and the desire for simultaneous clinical evaluation and implementation. In this paper we compare the potential benefits of SW-CRTs against the ethical and epistemic challenges brought forth by the design and suggest that the choice of SW-CRT design must balance epistemic, feasibility and ethical justifications. Moreover, given their complexity, such studies need rigorous and informed ethical oversight.
Copyright © 2022. Published by Elsevier Inc.

Entities:  

Keywords:  Clinical trial design; Ethics; Pragmatic clinical trials; Stepped-wedge cluster randomized trials

Mesh:

Year:  2022        PMID: 35176501      PMCID: PMC9272561          DOI: 10.1016/j.cct.2022.106703

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.261


  57 in total

1.  Oversight on the borderline: Quality improvement and pragmatic research.

Authors:  Jonathan A Finkelstein; Andrew L Brickman; Alexander Capron; Daniel E Ford; Adrijana Gombosev; Sarah M Greene; R Peter Iafrate; Laura Kolaczkowski; Sarah C Pallin; Mark J Pletcher; Karen L Staman; Miguel A Vazquez; Jeremy Sugarman
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

2.  Deciphering assumptions about stepped wedge designs: the case of Ebola vaccine research.

Authors:  Adélaïde Doussau; Christine Grady
Journal:  J Med Ethics       Date:  2016-10-17       Impact factor: 2.903

3.  Lumbar Imaging With Reporting Of Epidemiology (LIRE)--Protocol for a pragmatic cluster randomized trial.

Authors:  Jeffrey G Jarvik; Bryan A Comstock; Kathryn T James; Andrew L Avins; Brian W Bresnahan; Richard A Deyo; Patrick H Luetmer; Janna L Friedly; Eric N Meier; Daniel C Cherkin; Laura S Gold; Sean D Rundell; Safwan S Halabi; David F Kallmes; Katherine W Tan; Judith A Turner; Larry G Kessler; Danielle C Lavallee; Kari A Stephens; Patrick J Heagerty
Journal:  Contemp Clin Trials       Date:  2015-10-19       Impact factor: 2.226

Review 4.  Logistic, ethical, and political dimensions of stepped wedge trials: critical review and case studies.

Authors:  Audrey Prost; Ariella Binik; Ibrahim Abubakar; Anjana Roy; Manuela De Allegri; Christelle Mouchoux; Tobias Dreischulte; Helen Ayles; James J Lewis; David Osrin
Journal:  Trials       Date:  2015-08-17       Impact factor: 2.279

5.  Ethical and regulatory issues of pragmatic cluster randomized trials in contemporary health systems.

Authors:  Monique L Anderson; Robert M Califf; Jeremy Sugarman
Journal:  Clin Trials       Date:  2015-03-01       Impact factor: 2.486

6.  Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly (ACP-PEACE): the study protocol for a pragmatic stepped-wedge trial of older patients with cancer.

Authors:  Joshua R Lakin; Elise N Brannen; James A Tulsky; Michael K Paasche-Orlow; Charlotta Lindvall; Yuchiao Chang; Daniel A Gundersen; Areej El-Jawahri; Angelo Volandes
Journal:  BMJ Open       Date:  2020-07-14       Impact factor: 2.692

7.  The Effect of Including Benchmark Prevalence Data of Common Imaging Findings in Spine Image Reports on Health Care Utilization Among Adults Undergoing Spine Imaging: A Stepped-Wedge Randomized Clinical Trial.

Authors:  Jeffrey G Jarvik; Eric N Meier; Kathryn T James; Laura S Gold; Katherine W Tan; Larry G Kessler; Pradeep Suri; David F Kallmes; Daniel C Cherkin; Richard A Deyo; Karen J Sherman; Safwan S Halabi; Bryan A Comstock; Patrick H Luetmer; Andrew L Avins; Sean D Rundell; Brent Griffith; Janna L Friedly; Danielle C Lavallee; Kari A Stephens; Judith A Turner; Brian W Bresnahan; Patrick J Heagerty
Journal:  JAMA Netw Open       Date:  2020-09-01

8.  Introducing the new CONSORT extension for stepped-wedge cluster randomised trials.

Authors:  Karla Hemming; Monica Taljaard; Jeremy Grimshaw
Journal:  Trials       Date:  2019-01-18       Impact factor: 2.279

9.  User-centred clinical decision support to implement emergency department-initiated buprenorphine for opioid use disorder: protocol for the pragmatic group randomised EMBED trial.

Authors:  Edward R Melnick; Molly Moore Jeffery; James D Dziura; Jodi A Mao; Erik P Hess; Timothy F Platts-Mills; Yauheni Solad; Hyung Paek; Shara Martel; Mehul D Patel; Laura Bankowski; Charles Lu; Cynthia Brandt; Gail D'Onofrio
Journal:  BMJ Open       Date:  2019-05-30       Impact factor: 2.692

10.  The Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials.

Authors:  Charles Weijer; Jeremy M Grimshaw; Martin P Eccles; Andrew D McRae; Angela White; Jamie C Brehaut; Monica Taljaard
Journal:  PLoS Med       Date:  2012-11-20       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.